Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000249245 | SCV000320247 | uncertain significance | Cardiovascular phenotype | 2015-09-10 | criteria provided, single submitter | clinical testing | The p.E2655K variant (also known as c.7963G>A), located in coding exon 63 of the FBN2 gene, results from a G to A substitution at nucleotide position 7963. The glutamic acid at codon 2655 is replaced by lysine, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis.Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Genome Diagnostics Laboratory, |
RCV002278246 | SCV002565972 | uncertain significance | Ehlers-Danlos syndrome | 2020-02-01 | criteria provided, single submitter | clinical testing |